We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

65 hedge funds and large institutions have $75.5M invested in Gyre Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,982% more call options, than puts

Call options by funds: $5.11M | Put options by funds: $84K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.79% less ownership

Funds ownership: 8.61% → 7.81% (-0.79%)

6% less funds holding

Funds holding: 69 → 65 (-4)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

14% less capital invested

Capital invested by funds: $87.7M → $75.5M (-$12.2M)

71% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 31

Holders
65
Holders Change
-4
Holders Change %
-5.8%
% of All Funds
1.14%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
14
Increased
9
Reduced
31
Closed
16
Calls
$5.11M
Puts
$84K
Net Calls
+$5.03M
Net Calls Change
+$3.22M

Top Buyers

1
O
OrbiMed
New York
+$2.6M
2
PVI
Pura Vida Investments
New York
+$1.63M
3
SM
Sabby Management
Florida
+$464K
4
Citadel Advisors
Citadel Advisors
Florida
+$287K
5
JGC
J. Goldman & Co
New York
+$267K

Top Sellers

1
SCM
Stonepine Capital Management
Oregon
-$1.94M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.79M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.68M
4
ACP
Acuta Capital Partners
California
-$1.4M
5
PHP
Parkman Healthcare Partners
Connecticut
-$1.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
51
Stephens Inc
Arkansas
$69K -$197 -6 -0.3%
KM
52
Kalos Management
Georgia
$58K -$3.06K -93 -4%
CCM
53
Colorado Capital Management
Colorado
$56K – – –
Walleye Trading
54
Walleye Trading
New York
$56K +$59.3K +1,801 New
Commonwealth Equity Services
55
Commonwealth Equity Services
Massachusetts
$41K +$43.9K +1,333 New
SCM
56
Silverarc Capital Management
Massachusetts
$41K +$43.9K +1,333 New
SPIA
57
Steward Partners Investment Advisory
New York
$33K -$8.75K -266 -20%
CG
58
Cutler Group
California
$22K – – –
TCWM
59
Total Clarity Wealth Management
Illinois
$8K +$8.79K +267 New
CAGAS
60
Capital Advisory Group Advisory Services
Minnesota
$4K – – –
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$2.21K +$197 +6 +9%
Wells Fargo
62
Wells Fargo
California
$2K -$99 -3 -4%
JCM
63
Jacobi Capital Management
Pennsylvania
$1K – – –
APA
64
American Portfolios Advisors
New York
$884 +$954 +29 New
Walleye Capital
65
Walleye Capital
New York
$167 +$178K +5,403 New
Verition Fund Management
66
Verition Fund Management
Connecticut
– -$1.68M -51,613 Closed
Deutsche Bank
67
Deutsche Bank
Germany
– -$844K -25,991 Closed
TEE
68
Tibra Equities Europe
United Kingdom
– -$343K -10,560 Closed
Susquehanna International Group
69
Susquehanna International Group
Pennsylvania
– -$242K -7,363 Closed
TI
70
Trexquant Investment
Connecticut
– -$140K -4,296 Closed
PPA
71
Parametric Portfolio Associates
Washington
– -$91K -2,803 Closed
ASN
72
Advisory Services Network
Georgia
– -$85K -2,627 Closed
QSS
73
Quantitative Systematic Strategies
Florida
– -$70K -2,170 Closed
XT
74
XTX Topco
Cayman Islands
– -$66K -2,035 Closed
Charles Schwab
75
Charles Schwab
California
– -$57K -1,748 Closed
1 2
3
4

GYRE Hedge Fund Activity: Q3 2021 in Review

65 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2021, worth a combined $75.5M — down 14% from $87.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GYRE and 14 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 9 added.

The largest buyer was OrbiMed, adding an estimated $2.6M. The largest seller was Stonepine Capital Management, cutting an estimated $1.94M.

  • 65 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2021, down from 69 in Q2 2021.
  • Funds reported $75.5M of Gyre Therapeutics stock for Q3 2021, down 14% quarter-over-quarter.
  • 14 funds opened new Gyre Therapeutics positions in Q3 2021 and 16 closed out, a net change of -2 holders.
  • The largest Gyre Therapeutics buyer in Q3 2021 was OrbiMed, an estimated $2.6M added.
  • The largest Gyre Therapeutics seller in Q3 2021 was Stonepine Capital Management, an estimated $1.94M sold.

Based on aggregated 13F filings for Q3 2021.